AK
A recent study investigated the risk for developing nonmelanoma skin cancer, including actinic keratosis, among various outdoor professions.

News

News
Monday, October 22, 2018
A recent study investigated the risk for developing nonmelanoma skin cancer, including actinic keratosis, among various outdoor professions.
News
Wednesday, January 25, 2012
Ingenol mebutate (Picato) gel (0.015%, 0.05%) is the first and only topical AK therapy that can be used for as little as 2 or 3 days.
News
Monday, January 11, 2010
PhotoMedex and Galderma Laboratories, LP, have entered into a co-promotion agreement for Galderma’s photodynamic therapy application for the treatment of actinic keratoses (AKs). Under the terms of the agreement, the sales force at PhotoMedex will promote Galderma’s drug methyl aminolevulinate Cream 16.8% (Metvixia) and Galderma’s light-emitting diode (Aktilite CL128 LED) lamp to healthcare professionals, including dermatologists, plastic surgeons and cosmetic surgeons throughout the United States. Galderma will provide marketing support and distribution. The 3-year agreement begins in January
News
Thursday, September 4, 2008
Reducing Irritation While Effectively Treating AKs A new combination approach between topical 5-FU and hydrocortisone butyrate 0.1% lipocream. Traditionally, 5-fluorouracil (5-FU) cream is one modality that has been effectively used as a treatment for widespread actinic keratoses.1 Several treatment regimens have been used with topical 5-FU in the treatment of AKs.2,3,4 The common manner of topical 5-FU use has been morning and night application for 2 to 4 weeks.5 However, the high degree of irritation associated with its use may lead to treatment failures due to noncompliance or in

Research in Review

Research in Review
Monday, May 21, 2018
The Clinical Tips article includes suggestions for managing actinic keratoses, confirming a diagnosis of scabies, and more.
Research in Review
Tuesday, September 26, 2017
This article discusses the benefits and limitations of several new approaches using new and established field therapies for actinic keratoses.
Research in Review
Thursday, October 15, 2015
This case highlights the paramount importance of identifying and aggressively treating high-risk squamous cell carcinoma. 
Research in Review
Friday, February 3, 2012
Basal cell and squamous cell carcinomas (BCC and SCC, respectively) are the two most common forms, accounting for about 96% of non-melanoma skin cancer (NMSC). Dermatologists now have a variety of approaches that can be utilized for diagnosis, including optical coherence tomography (OCT), dermoscopy and biopsy, which remains the gold standard.